Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
DEVIL'S CLAW EXTRACT (AS DRY ROOT)
Bioforce (UK) Ltd
DEVIL'S CLAW EXTRACT (AS DRY ROOT)
480 Milligram
Film Coated Tablet
Product not subject to medical prescription
Authorised
2011-12-09
Bioforce UK Atrosan film-coated tablets GB – Irvine, Ayrshire CTD Module 1 July 2017 ___________________________________________________________________________________ PACKAGE LEAFLET Harpagophytum-Filmtabletten Page 1 of 5 Art. No. 01322600 PACKAGE LEAFLET: INFORMATION FOR THE USER ATROSAN Devil’s Claw film-coated tablets READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS PRODUCT BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this product exactly as described in this leaflet or as your doctor, pharmacist or nurse has told you. • Keep this leaflet. You may need to read it again. • Ask your pharmacist if you need more information or advice. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. • You must talk to a doctor if you do not feel better or if you feel worse after 4 weeks. WHAT IS IN THIS LEAFLET: 1. What Atrosan is and what it is used for 2. What you need to know before you take Atrosan 3. How to take Atrosan 4. Possible side effects 5. How to store Atrosan 6. Contents of the pack and other information 1. WHAT ATROSAN IS AND WHAT IT IS USED FOR Atrosan is a traditional herbal medicinal product containing the extract of Devil’s Claw root. It is used to relieve: • Minor joint pain This is exclusively based on long-standing use. Atrosan is for use in adults. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ATROSAN DO NOT TAKE ATROSAN • If you are allergic to: o Devil’s Claw (also known as Harpagophytum). This product contains Devil’s Claw root. o Any of the other ingredients of this product (listed in section 6). • If you have an ulcer (either a gastric and/or duodenal ulcer). Bioforce UK Atrosan film-coated tablets GB – Irvine, Ayrshire CTD Module 1 July 2017 ___________________________________________________________________________________ PACKAGE LEAFLET Harpagophytum-Filmtabletten Page 2 of 5 Art. No. 01322600 • If you are under 18 years of age. • If Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Atrosan Devil's Claw film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 480 mg of extract (as dry extract) from _Harpagophytum procumbens_ D.C. and/or H. zeyheri L. Decne, radix (Devil’s claw root). (1.5 – 3.0:1). Extraction solvent: Ethanol 60% v/v. Excipients with known effect: Each tablet contains 226.08 mg lactose monohydrate. For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Film-coated tablet (tablet) It is an oval-shaped, white coated tablet. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS A traditional herbal medicinal product for the relief of minor articular pain, exclusively based on long-standing use. This product is indicated for use in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY Adults and older people: One tablet twice daily immediately after food. The dose can be increased to two tablets twice daily if relief is not obtained after 3 to 5 days. This product is not indicated in patients less than 18 years old. If the condition worsens, new symptoms develop or symptoms persist during the use of Atrosan or for more than four weeks, a doctor should be consulted. METHOD OF ADMINISTRATION For oral short-term use only. 4.3 CONTRAINDICATIONS Do not use in cases of known hypersensitivity to the active substance or one of the excipients listed in section 6.1. Patients under 18 years of age. Pregnancy and lactation. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ Read the complete document